

Annual Report 2008-2009

Part 1: Identification

Working Group on: **MYOCARDIAL AND PERICARDIAL DISEASES**

Nucleus composition (name):

Chairperson: **Luigi Tavazzi**
Vice-chairperson: **Perry Elliott**
Past chairperson: **Andre Keren**
Treasurer: **Claudio Rapezzi**
Secretary: **Philippe Charron**
Web editor: **Sabine Pankuweit**
Nucleus Members: **Zofia Bilinska, Tiina Helio, Lorenzo Monserrat, Arsen Ristic, Hubert Segewiss**
Other (Senate...): **Eloisa Arbustini** (Affiliate Nucleus Member)

Part 2: Turn-Over of the WG during the year

Election: None

Part 3: Activities of the WG during the year

- ▶ **WG Annual Meeting(s): Florence (Italy) 22-24 May 2008**
- ▶ **Endorsed Meeting(s): Camogli (Italy) 4-5 April 2009**
- ▶ **Education programme(s) – Training, Courses & Grants: NO**
 - Publications / Guidelines / Scientific Papers **NO**
 - WG officially affiliated to a journal? **NO**
 - Number of WG Publications (e.g.: Reviews, Original Studies): **NONE**
 - Position Papers / Consensus Documents: **In preparation**
 - Participation to guidelines - writing / reviewing **NO**
- ▶ **Proposals for pre-arranged sessions at the ESC main congress and/or ESC Sub-specialty meetings: (A: accepted – R: rejected)**
 1. Advances in arrhythmogenic right ventricular cardiomyopathy (R)
 2. **Risk stratification and prevention of sudden death in cardiomyopathies (A)**
 3. Controversies in management of hypertrophic cardiomyopathy (R)
 4. **Diagnosis and management problems in patients and families with cardiomyopathy (A)**
 5. Genetic testing for cardiomyopathies in the clinical arena (R)
 6. Up-date for Tako-tsubo cardiomyopathy (R)
 7. Sport and cardiomyopathies: where are the limits? (R)
 8. Indications for endomyocardial biopsy revisited (R)
 9. **Treatment of recurrent pericardial effusion (A)**
 10. **Cardiology consultations in haematology (A)**
 11. Controversies in dilated cardiomyopathy (R)
 12. Is medical treatment for pulmonary arterial hypertension really effective? (R)
 13. Hypertrophic cardiomyopathy in the young (R)
 14. Effect of current-era therapies on morbid-mortality of different cardiovascular disease (R)

Part 4: Future projects:

- ▶ **2 further position papers**